Indian Journal of Chemical Technology

Open Access Open Access  Restricted Access Subscription Access

Stability Indicating HPLC Method for the Simultaneous Analysis of Gatifloxacin and Loteprednol in Eyedrop Formulation Using Design of Experiment Approach


Affiliations
1 Department of Pharma Chemistry, School of Pharmacy, RK University, Rajkot, Gujrat, India
2 Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Shaqra University, Alquwayiyah, Riyadh, Saudi Arabia
3 Department of Medical Laboratory Sciences, College of Applied Medical Sciences, Prince Sattam Bin Abdulaziz University, Al Kharj, Saudi Arabia
4 Clinical Pharmacy Department Umm Al-Qura University Makkah, Saudi Arabia
5 Department of Pharma Chemistry, P. Wadhwani College of Pharmacy, Maharashtra, India
 

Design of experiment (DOE) assisted simple, rapid, precise and accurate stability indicating HPLC method has been developed for simultaneous estimation of Gatifloxacin (GTF) and Loteprednol (LOT) along with their forced degradation products. The developed method has been optimized and developed by using central composite design (CCD) in response surface methodology (RSM). Trails have been undertaken and ratio of phosphate buffer in mobile phase, pH of buffer and flow rate are selected as factors. Resolution, tailing factor (GTF) and tailing factor (LOTE) are selected for determining the system response in the process of method optimization. The responses have been optimized using the Derringer’s desirability function. The effective separation is achieved on Phenomenex EVO-C18 column (250 mm x 4.6 mm i.d, 5 μm particle size) with mobile composed of 10 mM phosphate buffer, pH 3.5 and organic phase composed of mixture of acetonitrile and methanol 60:40 % v/v, the flow rate was 1.0 mL/min, the signals were detected at 267 nm. The developed method was validated for linearity, accuracy, precision, and robustness. The method was applied successfully for stability samples.

Keywords

Central Composite Design, Gatifloxacin, HPLC, Loteprednol.
User
Notifications
Font Size

  • Aljuffali I A, Kalam M A , Sultana Y, Imran A & Alshamsan A, Saudi Pharm J, 23 (2015) 85.

  • Diekema D J, Jones R N & Rolston K V, Diagn Microbiol Infect Dis, 34 (1999) 37.

  • Han Y K & Segall A I, J Chromatogr Sci, 53 (2015) 761.

  • Williams J R, Moore R H, Li R & Weeks C M, J Org Chemistry, 45 (1980) 2324.

  • Martindale, The Complete Drug reference, 32th Edn. Pharmaceutical Press, London, (1999) 1045.

  • Amin A S, El-Fetouh G A A, El-Sheikh R & Zahran F, Spectrochim Acta Part A, 67 (2007) 1306.

  • Fetouh G A A, El-Sheikh R & Amin A S, Chem Pharm Bull, 56 (2008) 34.

  • Flurer C L, Electrophoresis, 18 (1997) 2427.

  • Tasso L& Dalla C T, J Pharm Biomed Anal, 44 (2007) 205.

  • Motwani S K, Khar R K, Ahmad F J, Chopra S, Kohli K, Talegaonkar S& Iqbal Z, Anal Chim Acta, 576 (2006) 253.

  • Belal F, Al-Majed A A & Al-Obaid A M, Talanta, 50 (1999) 765.

  • Solanki R, Patel N, Patel M & Kothari C, NIRMA Univ J Pharm Sci, 5 (2018) 27.

  • Han Y K & Segall A I, J Chromatogr Sci, 53 (2015) 761.

  • Premakumari K B & Murugan V, Am J Pharm Tech Res, 5 (2015) 565.

  • Saxena V & Singh A, Int J Sci Res, 5 (2013) 252.

  • Joshi K A, Pradhan P K, Dey S D & Upadhyay U M, Asian J Pharma Res, 3 (2013) 9.

  • Patel Ankit B & Patel Dipti B, Asian J Res Chem, 6 (2013) 393.

  • International Conference on Harmonization (ICH); Validation of analytical procedures: Text and methodology. Q2 (R1), Geneva, Switzerland, (2005).

  • Bakshi M & Singh S, J Pharm Biomed Anal, 28 (2002) 1011.

  • International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. Validation of Analytical Procedures: Text and Methodology, Q2 (R1), Geneva, Switzerland, (2005).

  • Grace A C, Prabha T, Jagadeeswaran M, Srinivasan K & Sivakumar T, Int J Pharma Pharm Sci, 11 (2019) 1814.

  • Razzaq S N, Ashfaq M, Khan I U, Mariam I, Razzaq S S, Mustafa G, Zubair M, Braz J Pharm Sci, 53 (2017) 15177.

  • Khan I U, Razzaq S N, Mariam I, Ashfaq M & Razzaq S S, Quím Nova, 37 (2014) 349.

  • Dewani A P &Vekariya H J, J Chromatogr Sci, 16 (2022) 1.

  • Kashyap R & Srinivasa U, Int J Drug Develop Res, 6 (2014) 99.

  • Negi V, Chander V, Singh R, Sharma B, Singh P & Upadhaya K, Indian J Chem Technol, 24 (2017) 441.


Abstract Views: 126

PDF Views: 74




  • Stability Indicating HPLC Method for the Simultaneous Analysis of Gatifloxacin and Loteprednol in Eyedrop Formulation Using Design of Experiment Approach

Abstract Views: 126  |  PDF Views: 74

Authors

Anil P Dewani
Department of Pharma Chemistry, School of Pharmacy, RK University, Rajkot, Gujrat, India
Hitesh J Vekariya
Department of Pharma Chemistry, School of Pharmacy, RK University, Rajkot, Gujrat, India
Farhan R Khan
Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Shaqra University, Alquwayiyah, Riyadh, Saudi Arabia
Bashir Ibrahim A Omar
Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Shaqra University, Alquwayiyah, Riyadh, Saudi Arabia
Abdulkarim S Binshaya
Department of Medical Laboratory Sciences, College of Applied Medical Sciences, Prince Sattam Bin Abdulaziz University, Al Kharj, Saudi Arabia
Abdulfattah Yahya M Alhazmi
Clinical Pharmacy Department Umm Al-Qura University Makkah, Saudi Arabia
Mohammad Raghibul Hasan
Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Shaqra University, Alquwayiyah, Riyadh, Saudi Arabia
Bader Saud Alotaibi
Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Shaqra University, Alquwayiyah, Riyadh, Saudi Arabia
Anil V Chandewar
Department of Pharma Chemistry, P. Wadhwani College of Pharmacy, Maharashtra, India

Abstract


Design of experiment (DOE) assisted simple, rapid, precise and accurate stability indicating HPLC method has been developed for simultaneous estimation of Gatifloxacin (GTF) and Loteprednol (LOT) along with their forced degradation products. The developed method has been optimized and developed by using central composite design (CCD) in response surface methodology (RSM). Trails have been undertaken and ratio of phosphate buffer in mobile phase, pH of buffer and flow rate are selected as factors. Resolution, tailing factor (GTF) and tailing factor (LOTE) are selected for determining the system response in the process of method optimization. The responses have been optimized using the Derringer’s desirability function. The effective separation is achieved on Phenomenex EVO-C18 column (250 mm x 4.6 mm i.d, 5 μm particle size) with mobile composed of 10 mM phosphate buffer, pH 3.5 and organic phase composed of mixture of acetonitrile and methanol 60:40 % v/v, the flow rate was 1.0 mL/min, the signals were detected at 267 nm. The developed method was validated for linearity, accuracy, precision, and robustness. The method was applied successfully for stability samples.

Keywords


Central Composite Design, Gatifloxacin, HPLC, Loteprednol.

References